Results for tag: "Oncology Companion Diagnostic"

In the realm of biotechnology, the Oncology Companion Diagnostic market comprises medical devices and tests that are used alongside particular cancer therapies, allowing healthcare professionals to tailor treatment plans based on individual patient profiles. These diagnostics assist in determining the suitability of specific treatments for patients by identifying the presence of biomarkers associated with various forms of cancers. These markers can include genetic mutations, protein expression levels, and the presence of certain receptors on cancer cells. The employment of companion diagnostics is pivotal for precision medicine, as it enables the administration of targeted therapies, thus enhancing their effectiveness and minimizing potential side effects. This market involves an interdisciplinary approach, integrating advancements in molecular biology, pathology, and biomedical research to develop tests that facilitate decision-making in cancer treatment. Several companies are prominent players in the Oncology Companion Diagnostic market. Among them are Roche Diagnostic, Agilent Technologies, QIAGEN, Thermo Fisher Scientific, Illumina, Foundation Medicine, Myriad Genetics, and ArcherDX. These companies specialize in providing a diverse range of diagnostic tools and technologies that cater to the individual needs of cancer patients, advancing personalized healthcare. Show Less Read more